Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer

References

• Fradelos EC, Papathanasiou IV, Veneti A, et al. Psychological distress and resilience in women diagnosed with breast cancer in Greece. Asian Pac J Cancer Prev 2017;18:2545–50.
   PubMedGoogle Scholar
• Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res: CR 2008;27:32.
   PubMed Web of Science ®Google Scholar
• Sountharrajan S, Karthiga M, Suganya E, Rajan C. Automatic classification on bio medical prognosis of invasive breast cancer. Asian Pac J Cancer Prev 2017;18:2541–4.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Eisemann N, Waldmann A, Katalinic A. Epidemiology of breast cancer – current figures and trends. Geburtshilfe Frauenheilkd 2013;73:130–5.
   PubMed Web of Science ®Google Scholar
• Fan P, Maximov PY, Curpan RF, et al. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol Cell Endocrinol 2015;418:245–63.
   PubMed Web of Science ®Google Scholar
• Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014;23:128–36.
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Yamaguchi K, Ueno A, et al. A case of HER2-positive breast cancer with liver metastases showing three years of complete response to combination therapy with trastuzumab plus pertuzumab. Gan To Kagaku Ryoho 2018;45:459–61.
   PubMedGoogle Scholar
• Apuri S. Neoadjuvant and adjuvant therapies for breast cancer. South Med J 2017;110:638–42.
   PubMed Web of Science ®Google Scholar
• Sanchez-Spitman AB, Swen JJ, Dezentje VO, et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Rev Clin Pharmacol 2019;12:523–36.
   PubMed Web of Science ®Google Scholar
• Zheng L, Li X, Meng X, et al. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer. Mol Cell Endocrinol 2016;427:133–42.
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2016;2:1310–5.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Furuya H, Tamashiro PM, et al. Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model. Carcinogenesis 2018;39:47–55.
   PubMed Web of Science ®Google Scholar
• Geffken K, Spiegel S. Sphingosine kinase 1 in breast cancer. Adv Biol Regul 2018;67:59–65.
   PubMedGoogle Scholar
• Tsuchida J, Nagahashi M, Nakajima M, et al. Breast cancer sphingosine-1-phosphate is associated with phospho-sphingosine kinase 1 and lymphatic metastasis. J Surg Res 2016;205:85–94.
   PubMed Web of Science ®Google Scholar
• Sukocheva O, Wadham C, Holmes A, et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 2006;173:301–10.
   PubMed Web of Science ®Google Scholar
• Takabe K, Kim RH, Allegood JC, et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem 2010;285:10477–86.
   PubMed Web of Science ®Google Scholar
• Li J, Song Z, Wang Y, et al. Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway. Tumour Biol 2016;37:10587–93.
   PubMedGoogle Scholar
• Hatoum D, Haddadi N, Lin Y, et al. Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget. Oncotarget 2017;8:36898–929.
   PubMedGoogle Scholar
• Zhu YJ, You H, Tan JX, et al. Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer. Oncol Lett 2017;14:63–72.
   PubMed Web of Science ®Google Scholar
• Byun HS, Pyne S, Macritchie N, et al. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Medchemcomm 2013;4:1394.
   Web of Science ®Google Scholar
• Marfe G, Mirone G, Shukla A, Stefano C. Sphingosine kinases signalling in carcinogenesis. Mini Rev Med Chem 2015;15:300–14.
   PubMed Web of Science ®Google Scholar
• Pitman MR, Costabile M, Pitson SM. Recent advances in the development of sphingosine kinase inhibitors. Cell Signal 2016;28:1349–63.
   PubMed Web of Science ®Google Scholar
• Al-Dabbagh MM, Salim N, Himmat M, et al. Quantum probability ranking principle for ligand-based virtual screening. J Comput Aided Mol Des 2017;31:365–78.
   PubMed Web of Science ®Google Scholar
• Forli S, Huey R, Pique ME, et al. Computational protein–ligand docking and virtual drug screening with the AutoDock suite. Nat Prot 2016;11:905–19.
   PubMed Web of Science ®Google Scholar
• von Behren MM, Rarey M. Ligand-based virtual screening under partial shape constraints. J Comput Aided Mol Des 2017;31:335–47.
   PubMed Web of Science ®Google Scholar
• Lohning AE, Levonis SM, Williams-Noonan B, Schweiker SS. A practical guide to molecular docking and homology modelling for medicinal chemists. Curr Top Med Chem 2017;17:2023–40.
   PubMed Web of Science ®Google Scholar
• Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol 2008;443:365–82.
   PubMedGoogle Scholar
• Kontoyianni M. Docking and virtual screening in drug discovery. Methods Mol Biol 2017;1647:255–66.
   PubMedGoogle Scholar
• Liu X, Shi D, Zhou S, et al. Molecular dynamics simulations and novel drug discovery. Expert Opin Drug Discov 2018;13:23–37.
   PubMed Web of Science ®Google Scholar
• Khan FI, Wei DQ, Gu KR, et al. Current updates on computer aided protein modeling and designing. Int J Biol Macromol 2016;85:48–62.
   PubMed Web of Science ®Google Scholar
• Ali S, Khan FI, Mohammad T, et al. Identification and evaluation of inhibitors of lipase from Malassezia restricta using virtual high-throughput screening and molecular dynamics studies. Int J Mol Sci 2019;20:884.
   Web of Science ®Google Scholar
• Beg A, Khan FI, Lobb KA, et al. High throughput screening, docking, and molecular dynamics studies to identify potential inhibitors of human calcium/calmodulin-dependent protein kinase IV. J Biomol Struct Dyn 2019;37:2179–92.
   PubMed Web of Science ®Google Scholar
• Wang C, Greene D, Xiao L, et al. Recent developments and applications of the MMPBSA method. Front Mol Biosci 2018;4:87.
   PubMed Web of Science ®Google Scholar
• Ju T, Gao D, Fang ZY. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Biophys Res Commun 2016;470:728–34.
   PubMed Web of Science ®Google Scholar
• Wang J, Knapp S, Pyne NJ, et al. Crystal structure of sphingosine kinase 1 with PF-543. ACS Med Chem Lett 2014;5:1329–33.
   PubMed Web of Science ®Google Scholar
• Zoete V, Daina A, Bovigny C, Michielin O. SwissSimilarity: a web tool for low to ultra high throughput ligand-based virtual screening. J Chem Inf Model 2016;56:1399–404.
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42:D1091–7.
   PubMed Web of Science ®Google Scholar
• Feng Z, Chen L, Maddula H, et al. Ligand Depot: a data warehouse for ligands bound to macromolecules. Bioinformatics 2004;20:2153–5.
   PubMed Web of Science ®Google Scholar
• Bento AP, Gaulton A, Hersey A, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res 2014;42:D1083–90.
   PubMed Web of Science ®Google Scholar
• Degtyarenko K, de Matos P, Ennis M, et al. ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res 2007;36:D344–50.
   PubMed Web of Science ®Google Scholar
• Chan WK, Zhang H, Yang J, et al. GLASS: a comprehensive database for experimentally validated GPCR-ligand associations. Bioinformatics 2015;31:3035–42.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0 – The Human Metabolome Database in 2013. Nucleic Acids Res 2012;41:D801–7.
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012;52:1757–68.
   PubMed Web of Science ®Google Scholar
• Shahinozzaman M, Ishii T, Ahmed S, et al. A computational approach to explore and identify potential herbal inhibitors for the p21-activated kinase 1 (PAK1). J Biomol Struct Dyn 2019;1–21.
   PubMedGoogle Scholar
• Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem 2000;43:3867–77.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23.
   PubMed Web of Science ®Google Scholar
• Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1:55–68.
   PubMed Web of Science ®Google Scholar
• Egan WJ, Lauri G. Prediction of intestinal permeability. Adv Drug Deliv Rev 2002;54:273–89.
   PubMed Web of Science ®Google Scholar
• Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. J Med Chem 2001;44:1841–6.
   PubMed Web of Science ®Google Scholar
• Dahlin JL, Nissink JWM, Strasser JM, et al. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem 2015;58:2091–113.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Rizvi SM, Shakil S, Haneef M. A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. EXCLI J 2013;12:831–57.
   PubMed Web of Science ®Google Scholar
• Van Der Spoel D, Lindahl E, Hess B, et al. GROMACS: fast, flexible, and free. J Comput Chem 2005;26:1701–18.
   PubMed Web of Science ®Google Scholar
• Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. Acta Crystallogr D Biol Crystallogr 2004;60:1355–63.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33–8, 27–8.
   PubMed Web of Science ®Google Scholar
• Gramany V, Khan FI, Govender A, et al. Cloning, expression, and molecular dynamics simulations of a xylosidase obtained from Thermomyces lanuginosus. J Biomol Struct Dyn 2016;34:1681–92.
   PubMed Web of Science ®Google Scholar
• Khan FI, Aamir M, Wei DQ, et al. Molecular mechanism of Ras-related protein Rab-5A and effect of mutations in the catalytically active phosphate-binding loop. J Biomol Struct Dyn 2016;35:1–14.
   PubMed Web of Science ®Google Scholar
• Khan FI, Govender A, Permaul K, et al. Thermostable chitinase II from Thermomyces lanuginosus SSBP: cloning, structure prediction and molecular dynamics simulations. J Theor Biol 2015;374:107–14.
   PubMed Web of Science ®Google Scholar
• Khan FI, Nizami B, Anwer R, et al. Structure prediction and functional analyses of a thermostable lipase obtained from Shewanella putrefaciens. J Biomol Struct Dyn 2016;35:1–13.
   PubMed Web of Science ®Google Scholar
• Khan FI, Shahbaaz M, Bisetty K, et al. Large scale analysis of the mutational landscape in beta-glucuronidase: a major player of mucopolysaccharidosis type VII. Gene 2016;576:36–44.
   PubMed Web of Science ®Google Scholar
• Kumari R, Kumar R, Lynn A. g_mmpbsa – a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 2014;54:1951–62.
   PubMed Web of Science ®Google Scholar
• Kuzmanic A, Zagrovic B. Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors. Biophys J 2010;98:861–71.
   PubMed Web of Science ®Google Scholar
• Hubbard RE, Kamran Haider M. Hydrogen Bonds in Proteins: Role and Strength. In: Encyclopediaof Life Sciences (ELS), Chichester: John Wiley & Sons, Ltd.; 2010. doi:10.1002/9780470015902.a0003011.pub2
   Google Scholar
• Maisuradze GG, Liwo A, Scheraga HA. Principal component analysis for protein folding dynamics. J Mol Biol 2009;385:312–29.
   PubMed Web of Science ®Google Scholar
• David CC, Jacobs DJ. Principal component analysis: a method for determining the essential dynamics of proteins. Methods Mol Biol 2014;1084:193–226.
   PubMedGoogle Scholar
• Tiana G, Simona F, De Mori GM, et al. Understanding the determinants of stability and folding of small globular proteins from their energetics. Protein Sci 2004;13:113–24.
   PubMed Web of Science ®Google Scholar
• Chang YC, Chuang HL, Yin JH, et al. Significance of sphingosine kinase 1 expression in feline mammary tumors. BMC Vet Res 2019;15:155.
   PubMed Web of Science ®Google Scholar
• Kotelevets N, Fabbro D, Huwiler A, Zangemeister-Wittke U. Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis. PLoS One 2012;7:e39209.
   PubMed Web of Science ®Google Scholar
• Pinho FG, Frampton AE, Nunes J, et al. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. Cancer Res 2013;73:5936–48.
   PubMed Web of Science ®Google Scholar
• Costales MG, Hoch DG, Abegg D, et al. A designed small molecule inhibitor of a non-coding RNA sensitizes HER2 negative cancers to herceptin. J Am Chem Soc 2019;141:2960–74.
   PubMed Web of Science ®Google Scholar
• Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem 2014;57:5509–24.
   PubMed Web of Science ®Google Scholar
• Martin JL, de Silva HC, Lin MZ, et al. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther 2014;13:316–28.
   PubMed Web of Science ®Google Scholar
• Datta A, Loo SY, Huang B, et al. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget 2014;5:5920–33.
   PubMedGoogle Scholar
• Houck JD, Dawson TK, Kennedy AJ, et al. Structural requirements and docking analysis of amidine-based sphingosine kinase 1 inhibitors containing oxadiazoles. ACS Med Chem Lett 2016;7:487–92.
   PubMed Web of Science ®Google Scholar
• Gupta P, Mohammad T, Khan P, et al. Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: a targeted approach towards anticancer therapy. Biomed Pharmacother 2019;118:109245.
   PubMed Web of Science ®Google Scholar
• Schnute ME, McReynolds MD, Kasten T, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 2012;444:79–88.
   PubMed Web of Science ®Google Scholar
• Gupta P, Khan FI, Roy S, et al. Functional implications of pH-induced conformational changes in the Sphingosine kinase 1. Spectrochim Acta A: Mol Biomol Spectrosc 2020;225:117453.
   PubMed Web of Science ®Google Scholar
• Papaleo E. Integrating atomistic molecular dynamics simulations, experiments, and network analysis to study protein dynamics: strength in unity. Front Mol Biosci 2015;2:28.
   PubMed Web of Science ®Google Scholar
• Rose JA, Suyama A. Physical modeling of biomolecular computers: models, limitations, and experimental validation. Nat Comput 2004;3:411–26.
   Google Scholar